The UK has accounted for a 3.6% share of the global clinical trials activity in 2020, registering a decrease when compared with the last ten-year average of a 6.1% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials in UK
Industry sponsored trials held an 84.6% share of all the clinical trials in the UK in 2020, when compared with the ten-year average of 80.8%. Non-industry sponsored trials accounted for a 15.4% share in 2020 as against the average of 19.2% in the last ten years.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry sponsored clinical trials in UK
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOncology was the leading therapy area for industry sponsored clinical trials in the UK in 2020 with a 31.3% share, as against a five-year average of 31.0% and a ten-year average of 29.9%.
Infectious Disease held an 18.2% share in 2020, over a five-year average of 8.4% and a ten-year average of 9.5%.
Respiratory held a 10.7% share in 2020, compared to a five-year average of 8.1% and a ten-year average of 8.8%. Central Nervous System held a 9.8% share in 2020, as against a five-year average of 13.2% and a ten-year average of 12.9%.
Metabolic Disorders held a 6.4% share, over a five-year average of 6.8% and a ten-year average of 7.8%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for non-industry sponsored clinical trials in UK
Infectious Disease was the leading therapy area for non-industry sponsored clinical trials in the UK in 2020 with a 35.5% share, as against a five-year average of 12.0% and a ten-year average of 12.7%.
Cardiovascular held a 14.5% share in 2020, over a five-year average of 15.5% and a ten-year average of 16.0%.
Central Nervous System held a 14.5% share in 2020, compared to a five-year average of 23.4% and a ten-year average of 20.6%. Respiratory held a 14.5% share in 2020, as against a five-year average of 8.5% and a ten-year average of 8.6%.
Oncology held a 12.1% share, over a five-year average of 13.1% and a ten-year average of 14.5%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials lead industry sponsored clinical trials in UK in 2020
Phase II trials held a 38.7% share of industry sponsored clinical trials in the UK in 2020, over a five-year average of 37.5% and a ten-year average of 35.6%.
Phase III trials held a 38.4% share in 2020, as against a five-year average of 36.0% and a ten-year average of 35.7%. Phase I trials held a 17.3% share in 2020, compared to a five-year average of 18.7% and a ten-year average of 18.9%.
Phase IV trials held a 5.7% share in 2020, over a five-year average of 7.9% and a ten-year average of 9.9%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials lead non-industry sponsored clinical trials in UK in 2020
Phase II trials held a 50.0% share of non-industry sponsored clinical trials in the UK in 2020, over a five-year average of 50.7% and a ten-year average of 45.3%.
Phase IV trials held a 22.6% share in 2020, as against a five-year average of 25.5% and a ten-year average of 29.9%. Phase III trials held a 21.0% share, compared to a five-year average of 16.3% and a ten-year average of 16.6%.
Phase I held a 6.5% share in 2020, over a five-year average of 7.5% and a ten-year average of 8.2%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
